Artelo Biosciences (ARTL)
(Delayed Data from NSDQ)
$9.48 USD
-0.45 (-4.53%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $9.54 +0.06 (0.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARTL 9.48 -0.45(-4.53%)
Will ARTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTL
New Strong Sell Stocks for April 10th
New Strong Sell Stocks for March 28th
ARTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for March 6th
Other News for ARTL
Artelo Biosciences (ARTL): D. Boral Capital Adjusts Price Target, Maintains Buy Rating | ARTL ...
ARTL Implements Innovative Treasury Strategy with New Securities Purchase Agreement
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana ...
Artelo Biosciences announces private placement to initiate Solana treasury
Artelo Biosciences (ARTL) Advances ART12.11 with UK Regulatory Support